Montreal's McGill University Health Centre and Hôpital Maisonneuve-Rosemont manage multiple myeloma patients across Quebec requiring Lenalidomide-based therapy. Lenalid 25mg offers Montreal and Quebec City patients significant cost savings following Revlimid patent expiry, without compromising the clinical outcomes that have made Lenalidomide a backbone of myeloma treatment.
RAMQ's drug plan coverage of Lenalidomide can involve eligibility restrictions and prior authorisation, leaving gaps for some Quebec patients. Generic Lenalid provides an affordable alternative pathway to this essential myeloma medicine.
RAMQ's drug plan coverage of Lenalidomide can involve eligibility restrictions and prior authorisation, leaving gaps for some Quebec patients. Generic Lenalid provides an affordable alternative pathway to this essential myeloma medicine.
Can Lenalid be used for MDS (myelodysplastic syndrome) as well as myeloma?Yes — Lenalidomide has an important approved indication beyond myeloma: transfusion-dependent anaemia in MDS with deletion 5q (del(5q)), a specific chromosomal abnormality found in a subset of MDS patients. In this indication, Lenalidomide has demonstrated remarkable responses — over 60% of del(5q) MDS patients achieve transfusion independence — through mechanisms that appear to target the specific genetic driver of this MDS subtype. This del(5q) MDS indication uses different doses (typically 10mg daily) and has different monitoring requirements than the myeloma dosing. Montreal haematologists manage both conditions and assess eligibility for these distinct applications individually.
